Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
Levodopa-Carbidopa intestinal gel (LCIG) is an effective therapy for complicated Parkinson\'s disease (PD). Few studies have explored the efficacy and safety of the potential combination of LCIG with catechol-O-methyltransferase (COMT) inhibitors, particularly Opicapone (OPC).
Epistemonikos ID: 6a0b2f33a9856ae5084f1a6b8dd1d618e3f92168
First added on: Jun 01, 2024